278 related articles for article (PubMed ID: 23315293)
1. Pharmacovigilance in the Middle East: a survey of 13 arabic-speaking countries.
Wilbur K
Drug Saf; 2013 Jan; 36(1):25-30. PubMed ID: 23315293
[TBL] [Abstract][Full Text] [Related]
2. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 survey.
Qato DM
Int J Pharm Pract; 2018 Jun; 26(3):210-221. PubMed ID: 28737220
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. National pharmacovigilance programs in Arab countries: A quantitative assessment study.
Alshammari TM; Alenzi KA; Ata SI
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1001-1010. PubMed ID: 32181540
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries.
Alshammari TM; Mendi N; Alenzi KA; Alsowaida Y
Drug Saf; 2019 Jul; 42(7):849-868. PubMed ID: 31006085
[TBL] [Abstract][Full Text] [Related]
6. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
7. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
8. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
[TBL] [Abstract][Full Text] [Related]
9. Cross-national analysis of estimated narcotic utilization for twelve Arabic speaking countries in the Middle East.
Wilby KJ; Wilbur K
Saudi Pharm J; 2017 Jan; 25(1):83-87. PubMed ID: 28223866
[TBL] [Abstract][Full Text] [Related]
10. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Matos C; van Hunsel F; Joaquim J
Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
Olsson S; Pal SN; Stergachis A; Couper M
Drug Saf; 2010 Aug; 33(8):689-703. PubMed ID: 20635827
[TBL] [Abstract][Full Text] [Related]
12. Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia.
Adenuga BA; Kibuule D; Rennie TW
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):247-253. PubMed ID: 31520574
[TBL] [Abstract][Full Text] [Related]
13. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
Kant A; de Vries L; Rolfes L
Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance in India: Present Scenario and Future Challenges.
Kalaiselvan V; Srivastava S; Singh A; Gupta SK
Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
[TBL] [Abstract][Full Text] [Related]
16. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon.
Hajj A; Hallit S; Ramia E; Salameh P;
Curr Med Res Opin; 2018 Jan; 34(1):149-156. PubMed ID: 28758813
[TBL] [Abstract][Full Text] [Related]
17. A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms.
Chan CL; Ang PS; Li SC
Drug Saf; 2017 Jun; 40(6):517-530. PubMed ID: 28247278
[TBL] [Abstract][Full Text] [Related]
18. Kuwait.
United States. Department of State. Bureau of Public Affairs
Backgr Notes Ser; 1988 Mar; ():1-8. PubMed ID: 12177972
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
[TBL] [Abstract][Full Text] [Related]
20. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
